Method for stabilizing remission of alcohol dependence in patients with comorbid depression

Agomelatine's administration at 25 mg daily normalizes circadian rhythms and alleviates depressive symptoms in ADS with comorbid depression, stabilizing remission and reducing relapse risk by addressing sleep dysregulation and depression.

RU2865746C1Active Publication Date: 2026-07-08FEDERALNOE GOSUDARSTVENNOE BIUDZHETNOE UCHREZHDENIE NATSIONALNYI MEDITSINSKII ISSLEDOVATELSKII TSENTR PSIKHIATRII I NEVROLOGII IMENI V M BEKHTEREVA MINISTERSTVA ZDRAVOOKHRANENIIA ROSSIISKOI FEDERATSII
View PDF 1 Cites 0 Cited by

Patent Information

Authority / Receiving Office
RU · RU
Patent Type
Patents
Current Assignee / Owner
FEDERALNOE GOSUDARSTVENNOE BIUDZHETNOE UCHREZHDENIE NATSIONALNYI MEDITSINSKII ISSLEDOVATELSKII TSENTR PSIKHIATRII I NEVROLOGII IMENI V M BEKHTEREVA MINISTERSTVA ZDRAVOOKHRANENIIA ROSSIISKOI FEDERATSII
Filing Date
2025-06-26
Publication Date
2026-07-08

AI Technical Summary

Technical Problem

Current treatments for alcohol dependence syndrome (ADS) comorbid with depressive disorders do not effectively stabilize remission and address sleep dysregulation, despite the known importance of sleep disorders in relapse risk and quality of life, and lack systematic use of agomelatine as a circadian rhythm modulator.

Method used

Administering agomelatine, a dual-action drug as an MT1 and MT2 melatonin receptor agonist and 5-HT2C serotonin antagonist, at a fixed dose of 25 mg daily to normalize circadian rhythms and alleviate depressive symptoms, thereby stabilizing remission in ADS with comorbid depression.

Benefits of technology

Agomelatine effectively stabilizes remission in ADS with comorbid depression by improving sleep patterns and reducing depressive symptoms, extending the duration of remission and lowering relapse risk, as evidenced by clinical trials and actigraphy data.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

FIELD: psychiatry; narcology.SUBSTANCE: used to stabilize remission of alcohol dependence in patients with comorbid depression. After the withdrawal state with alcohol dependence syndrome and comorbid depressive disorder has been relieved, the patient takes agomelatine orally at a dosage of 25 mg once a day daily for 12 weeks.EFFECT: method is accessible and allows for stabilizing remission in patients with alcohol dependence syndrome and depressive disorder.1 cl
Need to check novelty before this filing date? Find Prior Art